Pharma's Almanac | Large Molecule

254 Articles Available

1 11

The PHASE Platform

How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success

PAO-05-24-CL-01

Outsourced Manufacturing

A Closer Look at Small Molecule Drug Substance and Drug Product Manufacturing

PAO-03-24-NI-02

Analytical Method Development

Harnessing Biologic Development Experience in Support of CDMO Clients: Rapid, Effective and Tailored Analytical Method Development

PAO-03-24-CL-09

Bispecific Antibodies

Accelerating the Development and Production of High-Quality Bispecific Antibodies

PAO-03-24-CL-01

Biologics Formulation

Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform

PAO-02-24-CL-02

Recombinant Antibody

Recombinant Antibody Technology is Crucial to Past and Future Success in Biopharma

PAO-01-24-CL-4

Glycosylation

S-Glyn™ : Optimizing N-Glycan Profiles and their Effector Functions Using a Design-of-Experiments Approach

PAO-12-23-CL-06

Strategic Partnership

Samsung Biologics and Kurma Partners Announce Strategic Partnership for Development and Manufacturing of Biologics for Kurma’s Portfolio Companies

PR-M10-23-06

Insect Cell Expression

Innovations in Baculovirus–Insect Cell Expression Systems

PAO-09-23-CL-01

Quality Culture

Does Your Biologics CDMO Truly Have a Culture of Quality?

PAO-07-23-CL-07

R&D

Integrating Digital Solutions to Streamline Biopharma Operations

PAO-07-23-CL-06

Leadership

Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer

PR-M06-23-02

Distribution

Redefining Innovation and Growth in Pharmaceutical Distribution

PAO-06-23-CL-03

Biomanufacturing

Biologics Outsourcing: Decision Drivers and Key Considerations

PAO-04-23-CL-01

Tumor Microenvironment

Harnessing the Power of the Tumor Microenvironment with First-in-Class Therapies

PAO-03-23-CL-01

Scale-Up

Scale-Up Expertise to Support Your Biologics Life Cycle

PAO-02-23-CL-06

Antibody Production

From Llamas to Yeast: Producing Functional Therapeutic Antibody Fragments in Saccharomyces cerevisiae

PAO-01-23-CL-05

Biomanufacturing

An Experienced CDMO Can Be a Differentiator in the Rapidly Growing Biologics Market

PAO-01-23-CL-04

Anti-Idiotype Antibodies

Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development

PAO-01-23-CL-01

Artificial Intelligence in Antibody Design

Accelerated and Cost-Effective Antibody Design Using Artificial Intelligence

PAO-11-022-CL-15

Biomanufacturing

New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!

PAO-11-022-CL-11

Multispecific Antibodies

Optimized Multispecific Antibody Design, Development, and Manufacturing

PAO-08-022-CL-04

Cell Line Development

Wheeler Bio Integrates the Solentim® Ecosystem by Advanced Instruments to Deliver the Highest Level of Consistency Across Their Cell Line Development Workflow

PR-M06-22-04

Recombinant Antibodies

Taking a Customer-Focused Approach to Custom Antibody Development and Manufacturing

PAO-04-022-CL-01

1 11

Large Molecule

254 Articles Available

Can't find what you're looking for? Try our advanced search.

The PHASE Platform

How Synergistic Collaborations Between Outsourcing Partners Can Accelerate Clinical Success

Outsourced Manufacturing

A Closer Look at Small Molecule Drug Substance and Drug Product Manufacturing

Analytical Method Development

Harnessing Biologic Development Experience in Support of CDMO Clients: Rapid, Effective and Tailored Analytical Method Development

Bispecific Antibodies

Accelerating the Development and Production of High-Quality Bispecific Antibodies

Biologics Formulation

Successful Formulation Development for Biologics Using a Unique Biophysical Prediction and Screening Platform

Recombinant Antibody

Recombinant Antibody Technology is Crucial to Past and Future Success in Biopharma

Glycosylation

S-Glyn™ : Optimizing N-Glycan Profiles and their Effector Functions Using a Design-of-Experiments Approach

Strategic Partnership

Samsung Biologics and Kurma Partners Announce Strategic Partnership for Development and Manufacturing of Biologics for Kurma’s Portfolio Companies

Insect Cell Expression

Innovations in Baculovirus–Insect Cell Expression Systems

Quality Culture

Does Your Biologics CDMO Truly Have a Culture of Quality?

R&D

Integrating Digital Solutions to Streamline Biopharma Operations

Leadership

Wheeler Bio Appoints Dr. Stewart McNaull as Chief Business Officer

Distribution

Redefining Innovation and Growth in Pharmaceutical Distribution

Biomanufacturing

Biologics Outsourcing: Decision Drivers and Key Considerations

Tumor Microenvironment

Harnessing the Power of the Tumor Microenvironment with First-in-Class Therapies

Scale-Up

Scale-Up Expertise to Support Your Biologics Life Cycle

Antibody Production

From Llamas to Yeast: Producing Functional Therapeutic Antibody Fragments in Saccharomyces cerevisiae

Biomanufacturing

An Experienced CDMO Can Be a Differentiator in the Rapidly Growing Biologics Market

Anti-Idiotype Antibodies

Rapid Supply of Anti-Idiotype Antibodies Facilitates Preclinical and Clinical Antibody-Based Drug Development

Artificial Intelligence in Antibody Design

Accelerated and Cost-Effective Antibody Design Using Artificial Intelligence

Biomanufacturing

New Name, Same Expertise: Goodwin Biotechnology is Becoming GBI!

Multispecific Antibodies

Optimized Multispecific Antibody Design, Development, and Manufacturing

Cell Line Development

Wheeler Bio Integrates the Solentim® Ecosystem by Advanced Instruments to Deliver the Highest Level of Consistency Across Their Cell Line Development Workflow

Recombinant Antibodies

Taking a Customer-Focused Approach to Custom Antibody Development and Manufacturing